Therapy outcome in patients with chronic hepatitis C: Role of therapy supervision by expert hepatologists

Journal of Viral Hepatitis

Volumn 14, Issue 9, 2007, Pages 633-638

  Sagir, A ^a   Heintges, T ^a   Akyazi, Z ^a   Oette, M ^a   Erhardt, A ^a   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Hepatitis C; Hepatologist; IFN; Ribavirin

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALGORITHM; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; CLINICAL COMPETENCE; COHORT STUDIES; FEMALE; GASTROENTEROLOGY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34547921266     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00854.x     Document Type: Article

References (17)

1. Heintges T, Wands J. Hepatitis C virus: epidemiology and transmission. Hepatology 1997 26 : 521 526.
2. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999 29 : 1311 1316.
3. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004 24 (Suppl. 2 97 104.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
6. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
7. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 1432.
8. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
9. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 1069.
10. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005 39 : S23 S27.
11. Anderson S, Nevins CL, Green LK, El-Zimaity H, Anand BS. Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection. Dig Dis Sci 2001 46 : 1393 1398.
12. Ascione A, De Luca M, Di Costanzo GG et al. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. Curr Pharm Des 2002 8 : 977 980.
13. Hadziyannis SJ, Papatheodoridis GV. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003 4 : 541 551.
14. Hofmann WP, Bock H, Weber C et al. Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists. Z Gastroenterol 2006 44 : 25 31.
15. Arenas JI, Vargas HE. Hepatitis C. Virus antiviral therapy in patients with cirrhosis. Gastroenterol Clin North Am 2004 33 : 549 562, ix.
16. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001 13 : 483 488.
17. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005 42 : 1406 1413.